DexCom (DXCM) Financials

DexCom logo
$81.61 -1.72 (-2.06%)
Closing price 04:00 PM Eastern
Extended Trading
$80.64 -0.97 (-1.19%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for DexCom

Annual Income Statements for DexCom

This table shows DexCom's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-58 -66 -50 -127 101 550 217 341 542 576 836
Consolidated Net Income / (Loss)
-58 -66 -50 -127 101 550 217 341 542 576 836
Net Income / (Loss) Continuing Operations
-58 -66 -50 -127 101 550 217 341 542 576 836
Total Pre-Tax Income
-58 -65 -49 -127 104 298 257 391 710 709 1,088
Total Operating Income
-57 -64 -43 -186 142 300 266 391 598 600 912
Total Gross Profit
278 378 492 664 932 1,280 1,681 1,883 2,289 2,438 2,802
Total Revenue
402 573 719 1,032 1,476 1,927 2,449 2,910 3,622 4,033 4,662
Operating Revenue
402 573 719 1,032 1,476 1,927 2,449 2,910 3,622 4,033 4,662
Total Cost of Revenue
124 195 226 368 545 647 768 1,027 1,333 1,595 1,860
Operating Cost of Revenue
124 195 226 368 545 647 768 1,027 1,333 1,595 1,860
Total Operating Expenses
336 442 535 850 789 981 1,415 1,492 1,691 1,838 1,890
Selling, General & Admin Expense
198 286 349 433 516 618 811 1,008 1,185 1,286 1,291
Research & Development Expense
138 156 185 417 274 360 604 484 506 552 599
Total Other Income / (Expense), net
-0.40 -1.00 -6.10 60 -38 -1.60 -9.00 -0.40 113 109 177
Other Income / (Expense), net
- - 6.70 2.40 26 16 -9.00 -0.40 113 109 177
Income Tax Expense
0.10 0.70 1.60 0.60 3.10 -252 40 50 169 133 252
Basic Earnings per Share
($0.72) ($0.78) ($0.58) ($1.44) $1.11 $1.46 $0.56 $0.88 $1.40 $1.46 $2.14
Weighted Average Basic Shares Outstanding
79.80M 83.60M 86.30M 88.20M 91.10M 377.50M 386.90M 389.40M 386M 393.60M 390.20M
Diluted Earnings per Share
($0.72) ($0.78) ($0.58) ($1.44) $1.10 $1.33 $0.53 $0.82 $1.30 $1.42 $2.09
Weighted Average Diluted Shares Outstanding
79.80M 83.60M 86.30M 88.20M 92.30M 420.40M 428.80M 427.50M 425.50M 412.70M 405.50M
Weighted Average Basic & Diluted Shares Outstanding
79.80M 83.60M 86.30M 88.20M 91.59M 96.18M 97.07M 386.41M 385.52M 390.77M 384.86M

Quarterly Income Statements for DexCom

This table shows DexCom's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
146 144 135 152 105 180 284 267 200 249 275
Consolidated Net Income / (Loss)
146 144 135 152 105 180 284 267 200 249 275
Net Income / (Loss) Continuing Operations
146 144 135 152 105 180 284 267 200 249 275
Total Pre-Tax Income
133 188 177 211 154 241 352 341 270 318 335
Total Operating Income
101 158 152 189 134 213 243 323 255 318 327
Total Gross Profit
562 627 594 656 589 689 731 793 750 830 864
Total Revenue
921 1,004 994 1,114 1,036 1,157 1,209 1,260 1,192 1,308 1,345
Operating Revenue
921 1,004 994 1,114 1,036 1,157 1,209 1,260 1,192 1,308 1,345
Total Cost of Revenue
359 378 400 458 447 468 478 467 442 478 480
Operating Cost of Revenue
359 378 400 458 447 468 478 467 442 478 480
Total Operating Expenses
461 469 442 467 455 476 489 470 495 512 537
Selling, General & Admin Expense
319 333 306 327 310 328 331 322 350 359 376
Research & Development Expense
142 136 135 140 145 148 158 148 145 153 162
Total Other Income / (Expense), net
31 30 25 22 21 29 110 18 14 -0.80 7.50
Other Income / (Expense), net
31 30 25 22 21 29 110 18 14 -0.80 7.50
Income Tax Expense
-14 44 43 60 49 61 69 73 70 68 60
Basic Earnings per Share
$0.38 $0.36 $0.34 $0.38 $0.27 $0.46 $0.73 $0.68 $0.52 $0.65 $0.73
Weighted Average Basic Shares Outstanding
390.20M 399.20M 394.20M 393.60M 391.10M 392.10M 391.10M 390.20M 385.10M 382.20M 374.70M
Diluted Earnings per Share
$0.36 $0.35 $0.34 $0.37 $0.27 $0.45 $0.70 $0.67 $0.51 $0.64 $0.72
Weighted Average Diluted Shares Outstanding
416.70M 416.80M 410.20M 412.70M 407.50M 408.20M 407.40M 405.50M 393.60M 390.10M 383.50M
Weighted Average Basic & Diluted Shares Outstanding
397.68M 400.73M 390.60M 390.77M 392.11M 392.16M 390.02M 384.86M 385.87M 377.36M 372.95M

Annual Cash Flow Statements for DexCom

This table details how cash moves in and out of DexCom's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
14 8.40 347 694 -691 372 235 -410 -76 40 312
Net Cash From Operating Activities
49 56 92 123 315 476 443 670 749 990 1,441
Net Cash From Continuing Operating Activities
49 56 92 123 310 476 443 670 749 990 1,441
Net Income / (Loss) Continuing Operations
-58 -66 -50 -127 101 550 217 341 542 576 836
Consolidated Net Income / (Loss)
-58 -66 -50 -127 101 550 217 341 542 576 836
Depreciation Expense
11 15 16 29 49 67 102 156 186 218 252
Non-Cash Adjustments To Reconcile Net Income
121 113 114 264 154 140 240 167 73 131 67
Changes in Operating Assets and Liabilities, net
-25 -6.30 2.60 -43 6.30 -281 -116 5.10 -52 65 286
Net Cash From Investing Activities
-52 -56 -144 -140 -1,015 -1,018 -216 -522 -507 -208 536
Net Cash From Continuing Investing Activities
-52 -56 -144 -140 -1,015 -1,018 -216 -522 -507 -208 536
Purchase of Property, Plant & Equipment
-33 -56 -66 -67 -180 -199 -389 -365 -237 -359 -364
Purchase of Investments
-45 -39 -172 -453 -2,030 -3,058 -2,473 -2,281 -3,220 -2,658 -1,266
Sale and/or Maturity of Investments
28 39 93 392 1,196 2,251 2,666 2,128 2,947 2,824 2,165
Other Investing Activities, net
- - - -1.00 -1.20 -11 10 0.20 1.90 -16 0.60
Net Cash From Financing Activities
17 8.10 399 710 11 912 10 -553 -319 -735 -1,686
Net Cash From Continuing Financing Activities
17 8.10 399 710 11 912 10 -553 -319 -735 -1,686
Repayment of Debt
-2.30 -2.30 -75 -1.90 -1.20 -9.40 -9.90 -17 -786 -13 -1,215
Repurchase of Common Equity
- 0.00 0.00 -100 - 0.00 0.00 -558 -689 -750 -500
Issuance of Debt
0.00 0.00 464 837 0.00 1,189 0.00 0.00 1,231 0.00 0.00
Issuance of Common Equity
19 10 10 195 12 15 20 23 27 28 28
Other Financing Activities, net
- 0.00 0.00 -219 - - 0.00 0.00 -101 0.00 0.00
Effect of Exchange Rate Changes
0.00 0.00 - - -0.70 2.10 -1.40 -5.80 1.50 -7.40 22
Cash Interest Paid
0.30 0.10 2.40 3.60 10 11 12 12 12 11 11
Cash Income Taxes Paid
0.10 0.10 1.40 2.30 4.80 3.60 17 114 212 198 94

Quarterly Cash Flow Statements for DexCom

This table details how cash moves in and out of DexCom's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
285 88 -318 -15 299 254 677 -918 199 -13 -144
Net Cash From Operating Activities
209 279 200 301 184 303 660 294 526 269 326
Net Cash From Continuing Operating Activities
209 279 200 301 184 303 660 294 526 269 326
Net Income / (Loss) Continuing Operations
146 144 135 152 105 180 284 267 200 249 275
Consolidated Net Income / (Loss)
146 144 135 152 105 180 284 267 200 249 275
Depreciation Expense
53 52 55 58 60 63 64 65 67 68 75
Non-Cash Adjustments To Reconcile Net Income
33 31 5.40 61 24 47 -37 34 44 50 45
Changes in Operating Assets and Liabilities, net
-23 53 4.20 31 -5.40 14 350 -72 215 -98 -69
Net Cash From Investing Activities
75 -189 210 -304 100 -64 193 307 -299 330 -77
Net Cash From Continuing Investing Activities
75 -189 210 -304 100 -64 193 307 -299 330 -77
Purchase of Property, Plant & Equipment
-57 -66 -111 -125 -87 -94 -81 -102 -77 -85 -53
Purchase of Investments
-992 -784 -307 -574 -463 -608 -194 -1.20 -690 -70 -191
Sale and/or Maturity of Investments
1,122 667 631 405 650 639 466 410 468 526 167
Net Cash From Financing Activities
4.70 -1.40 -737 -1.60 13 -1.70 -175 -1,522 -25 -607 -392
Net Cash From Continuing Financing Activities
4.70 -1.40 -737 -1.60 13 -1.70 -175 -1,522 -25 -607 -392
Repayment of Debt
-8.70 -1.40 -1.30 -1.60 -1.70 -1.70 -1.70 -1,209 -1.90 -1.90 -1.90
Repurchase of Common Equity
- - -750 - - - - -313 - - -400
Issuance of Common Equity
13 - 15 - 14 - 14 - 13 - 12
Other Financing Activities, net
- - - - 0.00 - - - -36 -1.80 -1.60
Effect of Exchange Rate Changes
-3.80 -1.00 8.60 -11 2.30 17 -1.10 3.80 -2.80 -4.90 -1.10

Annual Balance Sheets for DexCom

This table presents DexCom's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
292 403 904 1,916 2,395 4,291 4,933 5,392 6,265 6,485 6,340
Total Current Assets
231 280 745 1,700 1,969 3,425 3,684 3,669 4,426 4,301 4,033
Cash & Equivalents
86 95 442 1,137 446 818 1,053 642 566 606 918
Short-Term Investments
29 29 107 249 1,087 1,890 1,679 1,814 2,158 1,973 1,081
Accounts Receivable
74 102 134 227 286 429 514 713 974 1,006 1,216
Inventories, net
35 45 45 71 120 235 357 307 560 543 629
Prepaid Expenses
6.80 9.20 17 17 30 54 82 193 168 174 189
Plant, Property, & Equipment, net
55 109 146 183 321 515 802 1,056 1,113 1,340 1,560
Total Noncurrent Assets
6.00 13 14 33 104 350 447 667 726 843 747
Goodwill
3.70 11 12 19 19 19 27 26 25 23 24
Intangible Assets
2.20 - - - - - 32 173 135 103 71
Noncurrent Deferred & Refundable Income Taxes
- - - - 0.00 216 291 341 419 481 296
Other Noncurrent Operating Assets
0.10 2.10 1.70 15 86 115 99 127 146 236 356
Total Liabilities & Shareholders' Equity
292 403 904 1,916 2,395 4,291 4,933 5,392 6,265 6,485 6,340
Total Liabilities
71 119 485 1,253 1,512 2,464 2,891 3,260 4,196 4,382 3,594
Total Current Liabilities
67 102 139 222 360 614 721 1,839 1,556 2,932 2,143
Accounts Payable
39 68 87 147 256 481 573 902 1,346 1,585 1,944
Current Employee Benefit Liabilities
25 33 49 72 89 114 125 134 171 112 169
Other Current Liabilities
- - - 0.00 14 17 21 21 21 31 29
Total Noncurrent Liabilities
3.90 17 346 1,030 1,152 1,850 2,170 1,421 2,640 1,450 1,451
Long-Term Debt
- 0.00 328 1,010 1,060 1,667 1,982 1,198 2,434 1,237 1,241
Other Noncurrent Operating Liabilities
3.90 17 18 20 93 183 189 223 206 213 211
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
221 284 419 663 883 1,827 2,042 2,132 2,069 2,103 2,746
Total Preferred & Common Equity
221 284 419 663 883 1,827 2,042 2,132 2,069 2,103 2,746
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
221 284 419 663 883 1,827 2,042 2,132 2,069 2,103 2,746
Common Stock
777 906 1,094 1,561 1,676 2,125 2,109 2,259 3,515 2,094 2,282
Retained Earnings
-555 -621 -672 -799 -696 -202 139 480 1,021 1,598 2,434
Treasury Stock
- - 0.00 -100 -100 -100 -206 -595 -2,451 -1,581 -2,085
Accumulated Other Comprehensive Income / (Loss)
-0.30 -1.00 -2.60 1.50 2.30 3.20 0.50 -12 -17 -8.00 115

Quarterly Balance Sheets for DexCom

This table presents DexCom's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
6,265 6,482 6,799 6,354 6,485 6,752 7,327 7,500 6,633 6,455 6,239
Total Current Assets
4,426 4,621 4,848 4,263 4,301 4,554 5,030 5,220 4,332 4,087 3,916
Cash & Equivalents
566 851 939 621 606 905 1,159 1,836 1,118 1,105 961
Short-Term Investments
2,158 2,046 2,182 1,871 1,973 1,797 1,770 1,486 1,297 842 857
Accounts Receivable
974 979 945 1,002 1,006 1,155 1,349 1,110 1,089 1,258 1,186
Inventories, net
560 589 570 586 543 538 571 604 694 726 771
Prepaid Expenses
168 156 212 182 174 159 181 184 134 156 141
Plant, Property, & Equipment, net
1,113 1,109 1,183 1,319 1,340 1,365 0.00 1,471 1,560 1,577 1,543
Total Noncurrent Assets
726 753 768 772 843 833 2,297 809 742 792 780
Goodwill
25 23 23 24 23 23 24 24 24 24 24
Intangible Assets
135 123 115 106 103 95 87 79 63 102 89
Noncurrent Deferred & Refundable Income Taxes
419 461 476 487 481 487 496 376 296 304 305
Other Noncurrent Operating Assets
146 146 154 156 236 228 1,689 331 359 362 361
Total Liabilities & Shareholders' Equity
6,265 6,482 6,799 6,354 6,485 6,752 7,327 7,500 6,633 6,455 6,239
Total Liabilities
4,196 4,235 4,365 4,375 4,382 4,485 4,754 4,774 3,676 3,834 3,703
Total Current Liabilities
1,556 1,594 1,722 1,735 2,932 3,037 3,309 3,336 2,224 2,358 2,253
Accounts Payable
1,346 1,447 1,570 1,593 1,585 1,691 1,944 1,932 2,074 2,192 2,066
Current Employee Benefit Liabilities
171 111 116 106 112 111 129 170 122 136 160
Other Current Liabilities
21 21 22 22 23 23 23 24 28 30 27
Total Noncurrent Liabilities
2,640 2,641 2,643 2,640 1,450 1,448 1,445 1,438 1,453 1,476 1,451
Long-Term Debt
2,434 2,436 2,438 2,440 1,237 1,238 1,239 1,240 1,242 1,243 1,244
Other Noncurrent Operating Liabilities
206 205 205 201 213 210 206 198 211 233 207
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
2,069 2,247 2,434 1,979 2,103 2,267 2,573 2,726 2,957 2,621 2,535
Total Preferred & Common Equity
2,069 2,247 2,434 1,979 2,103 2,267 2,573 2,726 2,957 2,621 2,535
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
2,069 2,247 2,434 1,979 2,103 2,267 2,573 2,726 2,957 2,621 2,535
Common Stock
3,515 2,511 1,993 2,051 2,094 2,143 2,188 2,247 2,338 2,377 2,426
Retained Earnings
1,021 1,168 1,311 1,446 1,598 1,703 1,883 2,167 2,633 2,883 3,158
Treasury Stock
-2,451 - -832 -1,581 -1,581 -1,581 - -1,769 -2,121 -2,728 -3,133
Accumulated Other Comprehensive Income / (Loss)
-17 -37 -38 63 -8.00 2.20 84 82 106 90 86

Annual Metrics And Ratios for DexCom

This table displays calculated financial ratios and metrics derived from DexCom's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
55.09% 42.61% 25.33% 43.58% 43.08% 30.54% 27.08% 18.84% 24.49% 11.34% 15.60%
EBITDA Growth
-251.91% -5.86% 78.89% -1,402.91% 240.44% 76.04% -6.25% 52.37% 63.97% 3.38% 44.62%
EBIT Growth
-165.58% -11.91% 43.98% -413.69% 191.73% 87.08% -18.63% 52.18% 81.78% -0.20% 53.51%
NOPAT Growth
-165.58% -11.91% 33.49% -338.35% 205.87% 300.28% -59.38% 52.14% 33.39% 7.03% 43.68%
Net Income Growth
-157.14% -13.89% 23.48% -153.19% 179.54% 443.72% -60.54% 57.31% 58.70% 6.41% 45.14%
EPS Growth
-140.00% -8.33% 25.64% -148.28% 176.39% 443.72% -60.54% 54.72% 58.54% 9.23% 47.18%
Operating Cash Flow Growth
107.63% 14.69% 63.70% 33.91% 155.28% 51.22% -6.96% 51.30% 11.80% 32.20% 45.60%
Free Cash Flow Firm Growth
-120.45% -9.61% 29.50% -223.31% 107.76% 929.22% -260.66% 95.87% 2,870.59% -6.53% 124.38%
Invested Capital Growth
79.90% 47.83% 23.92% 45.16% 42.01% 92.18% 64.47% 27.32% 8.07% 10.45% 1.20%
Revenue Q/Q Growth
13.08% 7.58% 7.45% 12.79% 9.24% 5.83% 5.58% 4.19% 6.44% 2.00% 3.24%
EBITDA Q/Q Growth
1.91% -16.47% 73.86% -616.00% 369.06% 0.63% -22.12% 33.11% 18.24% -3.10% 11.37%
EBIT Q/Q Growth
0.00% -13.70% 40.92% -1,795.88% 236.27% -1.16% -30.67% 50.89% 20.75% -4.69% 13.49%
NOPAT Q/Q Growth
0.00% -13.70% 29.87% -1,736.15% 259.32% 91.63% -61.16% 38.66% 42.62% -15.16% 19.87%
Net Income Q/Q Growth
0.35% -15.70% -4.15% -394.21% 159.02% 137.86% -65.76% 39.78% 43.63% -15.36% 16.04%
EPS Q/Q Growth
0.00% -18.18% -1.75% -400.00% 158.51% 137.86% -65.76% 30.16% 32.65% -17.92% 16.76%
Operating Cash Flow Q/Q Growth
6.29% 3.69% 43.53% -5.74% 53.79% 6.33% -13.01% 4.15% 0.15% 20.42% -0.51%
Free Cash Flow Firm Q/Q Growth
-12.09% -6.15% 24.49% -284.62% 107.24% 36.60% -1,163.91% 65.10% 106.07% 29.70% 2.58%
Invested Capital Q/Q Growth
30.64% 19.03% 8.89% 23.98% 7.21% 45.21% 13.23% 15.79% 12.28% 1.99% 7.42%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
69.25% 66.00% 68.49% 64.36% 63.11% 66.44% 68.63% 64.72% 63.19% 60.46% 60.10%
EBITDA Margin
-11.47% -8.51% -1.43% -15.01% 14.73% 19.86% 14.65% 18.79% 24.75% 22.98% 28.75%
Operating Margin
-14.20% -11.15% -5.92% -18.06% 9.64% 15.54% 10.86% 13.44% 16.50% 14.88% 19.56%
EBIT Margin
-14.20% -11.15% -4.98% -17.83% 11.43% 16.38% 10.49% 13.43% 19.61% 17.58% 23.35%
Profit (Net Income) Margin
-14.33% -11.44% -6.99% -12.32% 6.85% 28.53% 8.86% 11.73% 14.95% 14.29% 17.94%
Tax Burden Percent
100.17% 101.08% 103.29% 100.47% 97.03% 184.53% 84.46% 87.31% 76.22% 81.27% 76.84%
Interest Burden Percent
100.70% 101.56% 135.75% 68.79% 61.77% 94.39% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 2.98% -84.53% 15.54% 12.69% 23.78% 18.73% 23.16%
Return on Invested Capital (ROIC)
-47.44% -33.33% -16.60% -53.62% 39.62% 92.49% 21.60% 23.25% 26.61% 26.05% 35.45%
ROIC Less NNEP Spread (ROIC-NNEP)
-29.16% -15.69% -4.73% -54.73% 48.33% 92.88% 22.45% 23.30% 4.46% -15.35% 5.15%
Return on Net Nonoperating Assets (RNNOA)
15.57% 7.35% 2.32% 30.14% -26.54% -51.91% -10.39% -6.90% -0.82% 1.57% -0.95%
Return on Equity (ROE)
-31.88% -25.98% -14.28% -23.48% 13.08% 40.58% 11.21% 16.35% 25.78% 27.63% 34.50%
Cash Return on Invested Capital (CROIC)
-104.53% -71.93% -37.96% -90.46% 4.90% 29.40% -27.15% -0.79% 18.85% 16.12% 34.25%
Operating Return on Assets (OROA)
-23.96% -18.39% -5.48% -13.04% 7.83% 9.44% 5.57% 7.57% 12.19% 11.12% 16.97%
Return on Assets (ROA)
-24.17% -18.88% -7.68% -9.01% 4.69% 16.44% 4.70% 6.61% 9.29% 9.04% 13.04%
Return on Common Equity (ROCE)
-31.88% -25.98% -14.28% -23.48% 13.08% 40.58% 11.21% 16.35% 25.78% 27.63% 34.50%
Return on Equity Simple (ROE_SIMPLE)
-26.04% -23.11% -11.97% -19.16% 11.45% 30.10% 10.62% 16.01% 26.18% 27.40% 0.00%
Net Operating Profit after Tax (NOPAT)
-40 -45 -30 -130 138 553 225 342 456 488 701
NOPAT Margin
-9.94% -7.80% -4.14% -12.64% 9.35% 28.68% 9.17% 11.74% 12.58% 12.09% 15.03%
Net Nonoperating Expense Percent (NNEP)
-18.28% -17.64% -11.87% 1.11% -8.71% -0.39% -0.85% -0.06% 22.15% 41.40% 30.30%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - 8.33% 10.12% 10.73% 17.57%
Cost of Revenue to Revenue
30.75% 34.00% 31.51% 35.64% 36.89% 33.56% 31.37% 35.28% 36.81% 39.54% 39.90%
SG&A Expenses to Revenue
49.25% 49.92% 48.60% 41.95% 34.94% 32.09% 33.10% 34.63% 32.73% 31.88% 27.69%
R&D to Revenue
34.20% 27.23% 25.80% 40.46% 18.53% 18.68% 24.68% 16.64% 13.96% 13.70% 12.85%
Operating Expenses to Revenue
83.46% 77.15% 74.41% 82.42% 53.47% 50.90% 57.78% 51.27% 46.69% 45.58% 40.54%
Earnings before Interest and Taxes (EBIT)
-57 -64 -36 -184 169 316 257 391 710 709 1,088
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-46 -49 -10 -155 217 383 359 547 896 927 1,340
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
7.52 4.45 2.97 4.01 5.67 4.86 6.37 20.52 23.18 14.45 9.43
Price to Tangible Book Value (P/TBV)
7.73 4.63 3.06 4.13 5.79 4.91 6.56 22.63 25.12 15.37 9.76
Price to Revenue (P/Rev)
4.14 2.20 1.74 2.58 3.39 4.61 5.31 15.03 13.24 7.53 5.55
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 49.51 16.15 59.98 128.19 88.54 52.72 30.95
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 2.02% 6.19% 1.67% 0.78% 1.13% 1.90% 3.23%
Enterprise Value to Invested Capital (EV/IC)
14.33 7.11 5.17 7.94 11.08 9.97 9.48 26.28 26.79 15.39 12.64
Enterprise Value to Revenue (EV/Rev)
3.86 1.98 1.43 2.22 3.07 4.07 5.01 14.86 13.16 7.50 5.39
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 20.84 20.47 34.17 79.12 53.16 32.63 18.75
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 26.86 24.83 47.75 110.68 67.08 42.65 23.09
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 32.82 14.18 54.62 126.64 104.60 62.01 35.87
Enterprise Value to Operating Cash Flow (EV/OCF)
31.67 20.25 11.15 18.55 14.41 16.47 27.71 64.61 63.67 30.56 17.44
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 265.53 44.61 0.00 0.00 147.63 100.22 37.12
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.01 0.00 0.78 1.52 1.20 0.91 0.97 0.92 1.18 1.16 0.45
Long-Term Debt to Equity
0.00 0.00 0.78 1.52 1.20 0.91 0.97 0.56 1.18 0.59 0.45
Financial Leverage
-0.53 -0.47 -0.49 -0.55 -0.55 -0.56 -0.46 -0.30 -0.18 -0.10 -0.18
Leverage Ratio
1.32 1.38 1.86 2.60 2.79 2.47 2.38 2.47 2.78 3.06 2.65
Compound Leverage Factor
1.33 1.40 2.52 1.79 1.72 2.33 2.38 2.47 2.78 3.06 2.65
Debt to Total Capital
1.03% 0.00% 43.86% 60.37% 54.56% 47.72% 49.25% 48.03% 54.06% 53.73% 31.12%
Short-Term Debt to Total Capital
1.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 18.83% 0.00% 26.51% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 43.86% 60.37% 54.56% 47.72% 49.25% 29.20% 54.06% 27.22% 31.12%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
98.97% 100.00% 56.14% 39.63% 45.44% 52.28% 50.75% 51.97% 45.94% 46.27% 68.88%
Debt to EBITDA
-0.05 0.00 -31.81 -6.53 4.87 4.36 5.52 3.60 2.72 2.63 0.93
Net Debt to EBITDA
2.45 0.00 21.46 2.42 -2.18 -2.72 -2.09 -0.89 -0.32 -0.15 -0.57
Long-Term Debt to EBITDA
0.00 0.00 -31.81 -6.53 4.87 4.36 5.52 2.19 2.72 1.33 0.93
Debt to NOPAT
-0.06 0.00 -11.01 -7.75 7.68 3.02 8.83 5.77 5.34 5.01 1.77
Net Debt to NOPAT
2.82 0.00 7.43 2.88 -3.43 -1.88 -3.34 -1.42 -0.64 -0.28 -1.08
Long-Term Debt to NOPAT
0.00 0.00 -11.01 -7.75 7.68 3.02 8.83 3.51 5.34 2.54 1.77
Altman Z-Score
12.85 5.63 1.97 1.84 3.23 3.57 4.13 9.36 8.59 5.74 6.52
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
3.46 2.73 5.36 7.64 5.47 5.58 5.11 1.99 2.84 1.47 1.88
Quick Ratio
2.83 2.20 4.92 7.25 5.05 5.11 4.50 1.72 2.38 1.22 1.50
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-88 -97 -68 -220 17 176 -282 -12 323 302 677
Operating Cash Flow to CapEx
147.15% 100.90% 139.39% 183.61% 174.72% 239.00% 113.69% 183.53% 316.36% 275.78% 396.34%
Free Cash Flow to Firm to Interest Expense
-220.18 -96.53 -5.32 -9.69 0.28 9.92 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
122.50 56.20 7.19 5.43 5.22 26.87 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
39.25 0.50 2.03 2.47 2.23 15.63 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
1.69 1.65 1.10 0.73 0.68 0.58 0.53 0.56 0.62 0.63 0.73
Accounts Receivable Turnover
6.90 6.52 6.09 5.72 5.75 5.39 5.19 4.74 4.29 4.07 4.20
Inventory Turnover
4.83 4.84 5.00 6.35 5.72 3.65 2.59 3.09 3.08 2.89 3.18
Fixed Asset Turnover
9.36 6.99 5.64 6.28 5.85 4.61 3.72 3.13 3.34 3.29 3.22
Accounts Payable Turnover
4.17 3.64 2.92 3.14 2.70 1.75 1.46 1.39 1.19 1.09 1.05
Days Sales Outstanding (DSO)
52.89 55.96 59.94 63.86 63.43 67.71 70.27 76.99 85.01 89.58 86.98
Days Inventory Outstanding (DIO)
75.60 75.47 73.03 57.52 63.85 100.06 140.68 118.03 118.57 126.13 114.96
Days Payable Outstanding (DPO)
87.56 100.19 125.19 116.29 135.24 208.16 250.49 262.15 307.58 335.36 346.25
Cash Conversion Cycle (CCC)
40.93 31.24 7.79 5.10 -7.96 -40.39 -39.54 -67.13 -104.01 -119.65 -144.32
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
108 160 198 288 409 786 1,293 1,646 1,779 1,965 1,988
Invested Capital Turnover
4.77 4.27 4.01 4.24 4.24 3.22 2.36 1.98 2.12 2.15 2.36
Increase / (Decrease) in Invested Capital
48 52 38 90 121 377 507 353 133 186 24
Enterprise Value (EV)
1,552 1,138 1,026 2,286 4,532 7,835 12,261 43,254 47,655 30,239 25,128
Market Capitalization
1,665 1,262 1,247 2,661 5,005 8,876 13,011 43,740 47,945 30,377 25,885
Book Value per Share
$2.72 $3.36 $4.83 $7.47 $9.64 $19.02 $21.07 $5.52 $5.35 $5.38 $7.04
Tangible Book Value per Share
$2.65 $3.22 $4.69 $7.26 $9.44 $18.82 $20.47 $5.00 $4.94 $5.06 $6.80
Total Capital
224 284 747 1,674 1,942 3,494 4,024 4,102 4,503 4,544 3,987
Total Debt
2.30 0.00 328 1,010 1,060 1,667 1,982 1,970 2,434 2,441 1,241
Total Long-Term Debt
0.00 0.00 328 1,010 1,060 1,667 1,982 1,198 2,434 1,237 1,241
Net Debt
-113 -124 -221 -375 -474 -1,041 -749 -486 -290 -138 -758
Capital Expenditures (CapEx)
33 56 66 67 180 199 389 365 237 359 364
Debt-free, Cash-free Net Working Capital (DFCFNWC)
52 54 57 92 76 103 232 146 146 -5.60 -108
Debt-free Net Working Capital (DFNWC)
167 178 606 1,477 1,609 2,811 2,964 2,602 2,870 2,574 1,891
Net Working Capital (NWC)
164 178 606 1,477 1,609 2,811 2,964 1,830 2,870 1,369 1,891
Net Nonoperating Expense (NNE)
18 21 20 -3.31 37 2.95 7.60 0.35 -86 -89 -136
Net Nonoperating Obligations (NNO)
-113 -124 -221 -375 -474 -1,041 -749 -486 -290 -138 -758
Total Depreciation and Amortization (D&A)
11 15 26 29 49 67 102 156 186 218 252
Debt-free, Cash-free Net Working Capital to Revenue
12.81% 9.40% 7.96% 8.87% 5.14% 5.35% 9.49% 5.01% 4.03% -0.14% -2.31%
Debt-free Net Working Capital to Revenue
41.47% 30.98% 84.31% 143.19% 109.02% 145.88% 121.04% 89.43% 79.23% 63.82% 40.56%
Net Working Capital to Revenue
40.90% 30.98% 84.31% 143.19% 109.02% 145.88% 121.04% 62.87% 79.23% 33.95% 40.56%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.72) ($0.78) ($0.58) ($1.44) $1.11 $5.23 $1.60 $0.88 $1.40 $1.46 $2.14
Adjusted Weighted Average Basic Shares Outstanding
81.74M 84.82M 87.00M 90.00M 91.10M 94.40M 96.70M 389.40M 386M 393.60M 390.20M
Adjusted Diluted Earnings per Share
($0.72) ($0.78) ($0.58) ($1.44) $1.10 $5.06 $1.55 $0.82 $1.30 $1.42 $2.09
Adjusted Weighted Average Diluted Shares Outstanding
81.74M 84.82M 87.00M 90.00M 92.30M 97.50M 100.10M 427.50M 425.50M 412.70M 405.50M
Adjusted Basic & Diluted Earnings per Share
($0.72) ($0.78) ($0.58) ($1.44) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
79.80M 83.60M 86.30M 88.20M 91.59M 96.18M 97.07M 386.41M 385.52M 390.77M 384.86M
Normalized Net Operating Profit after Tax (NOPAT)
-40 -45 -30 -130 138 210 225 342 456 488 701
Normalized NOPAT Margin
-9.94% -7.80% -4.14% -12.64% 9.35% 10.88% 9.17% 11.74% 12.58% 12.09% 15.03%
Pre Tax Income Margin
-14.30% -11.32% -6.76% -12.26% 7.06% 15.46% 10.49% 13.43% 19.61% 17.58% 23.35%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-142.75 -63.90 -2.80 -8.10 2.80 17.83 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
-99.93 -44.73 -2.32 -5.74 2.29 31.22 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
-226.00 -119.60 -7.95 -11.06 -0.19 6.59 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
-183.18 -100.43 -7.48 -8.70 -0.70 19.98 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% -78.68% 0.00% 0.00% 0.00% 163.45% 127.18% 130.16% 59.79%

Quarterly Metrics And Ratios for DexCom

This table displays calculated financial ratios and metrics derived from DexCom's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
- - - - - - - - 384,864,842.00 385,872,977.00 377,360,765.00
DEI Adjusted Shares Outstanding
- - - - - - - - 384,864,842.00 385,872,977.00 377,360,765.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - - 0.52 0.65 0.73
Growth Metrics
- - - - - - - - - - -
Revenue Growth
24.21% 15.26% 1.97% 7.64% 12.49% 15.21% 21.64% 13.12% 15.05% 13.08% 11.18%
EBITDA Growth
74.36% 18.18% -19.37% -9.91% 15.84% 26.76% 78.73% 50.84% 57.07% 26.83% -1.61%
EBIT Growth
105.43% 17.89% -26.21% -14.18% 16.45% 28.38% 98.59% 61.24% 74.66% 31.69% -5.00%
NOPAT Growth
214.09% 29.54% 11.78% -39.94% -18.24% 31.32% 69.39% 86.86% 106.93% 57.51% 37.67%
Net Income Growth
201.23% 23.81% 11.52% -40.81% -28.01% 25.30% 110.85% 76.20% 89.28% 38.54% -3.07%
EPS Growth
200.00% 25.00% 17.24% -43.94% -25.00% 28.57% 105.88% 81.08% 88.89% 42.22% 2.86%
Operating Cash Flow Growth
34.62% 46.82% -25.89% 125.60% -12.14% 8.45% 230.78% -2.46% 185.96% -11.16% -50.66%
Free Cash Flow Firm Growth
73.07% 135.45% -280.35% -154.07% -260.97% -571.54% 219.44% 557.05% 415.13% 335.57% -41.47%
Invested Capital Growth
9.04% 4.96% 21.59% 10.45% 12.47% 19.26% -3.92% 1.20% -11.20% -8.22% 5.97%
Revenue Q/Q Growth
-10.97% 9.04% -1.01% 12.00% -6.96% 11.69% 4.51% 4.16% -5.37% 9.77% 2.76%
EBITDA Q/Q Growth
-38.27% 29.68% -3.00% 15.64% -20.36% 41.90% 36.76% -2.40% -17.07% 14.59% 6.09%
EBIT Q/Q Growth
-46.40% 41.74% -5.54% 19.11% -26.98% 56.25% 46.12% -3.29% -20.90% 17.81% 5.42%
NOPAT Q/Q Growth
-50.53% 8.08% -4.47% 17.59% -32.66% 73.60% 23.21% 29.72% -25.42% 32.14% 7.69%
Net Income Q/Q Growth
-42.88% -1.98% -6.20% 12.70% -30.52% 70.59% 57.84% -5.81% -25.36% 24.86% 10.44%
EPS Q/Q Growth
-45.45% -2.78% -2.86% 8.82% -27.03% 66.67% 55.56% -4.29% -23.88% 25.49% 12.50%
Operating Cash Flow Q/Q Growth
56.59% 33.56% -28.60% 51.08% -39.02% 64.85% 117.79% -55.45% 78.78% -48.78% 20.95%
Free Cash Flow Firm Q/Q Growth
-139.13% 204.22% -697.88% 77.83% -161.27% -36.14% 251.44% -15.15% 80.14% 1.77% -62.37%
Invested Capital Q/Q Growth
0.40% -1.93% 9.99% 1.99% 2.23% 4.00% -11.39% 7.42% -10.30% 7.50% 2.30%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
61.01% 62.40% 59.73% 58.90% 56.85% 59.53% 60.48% 62.93% 62.95% 63.44% 64.29%
EBITDA Margin
20.09% 23.89% 23.41% 24.17% 20.69% 26.28% 34.39% 32.22% 28.24% 29.48% 30.44%
Operating Margin
10.98% 15.73% 15.29% 16.96% 12.91% 18.37% 20.05% 25.64% 21.42% 24.33% 24.34%
EBIT Margin
14.39% 18.70% 17.84% 18.98% 14.89% 20.84% 29.13% 27.05% 22.61% 24.27% 24.89%
Profit (Net Income) Margin
15.90% 14.29% 13.54% 13.62% 10.17% 15.54% 23.47% 21.22% 16.74% 19.04% 20.46%
Tax Burden Percent
110.49% 76.41% 75.87% 71.79% 68.31% 74.57% 80.56% 78.46% 74.03% 78.46% 82.19%
Interest Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate
-10.49% 23.59% 24.13% 28.21% 31.69% 25.43% 19.44% 21.54% 25.97% 21.54% 17.81%
Return on Invested Capital (ROIC)
26.94% 27.66% 26.13% 26.24% 19.27% 30.69% 38.63% 47.46% 40.29% 47.35% 53.57%
ROIC Less NNEP Spread (ROIC-NNEP)
20.37% 23.58% 20.90% 18.73% 15.36% 27.05% 19.56% 44.36% 38.82% 47.46% 52.72%
Return on Net Nonoperating Assets (RNNOA)
-4.80% -5.80% -3.62% -1.92% -2.45% -6.31% -3.86% -8.19% -10.64% -10.86% -14.52%
Return on Equity (ROE)
22.14% 21.87% 22.51% 24.32% 16.83% 24.39% 34.77% 39.26% 29.65% 36.49% 39.05%
Cash Return on Invested Capital (CROIC)
22.61% 28.10% 13.25% 16.12% 12.68% 8.51% 34.94% 34.25% 54.00% 52.98% 44.61%
Operating Return on Assets (OROA)
9.12% 10.80% 10.90% 12.01% 9.34% 12.69% 18.99% 19.67% 16.28% 17.50% 18.50%
Return on Assets (ROA)
10.07% 8.26% 8.27% 8.62% 6.38% 9.46% 15.30% 15.43% 12.05% 13.73% 15.20%
Return on Common Equity (ROCE)
22.14% 21.87% 22.51% 24.32% 16.83% 24.39% 34.77% 39.26% 29.65% 36.49% 39.05%
Return on Equity Simple (ROE_SIMPLE)
28.45% 27.40% 34.40% 0.00% 23.61% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
112 121 115 136 91 159 195 253 189 250 269
NOPAT Margin
12.13% 12.02% 11.60% 12.18% 8.82% 13.70% 16.15% 20.12% 15.86% 19.09% 20.00%
Net Nonoperating Expense Percent (NNEP)
6.57% 4.09% 5.23% 7.52% 3.91% 3.64% 19.06% 3.10% 1.47% -0.11% 0.85%
Return On Investment Capital (ROIC_SIMPLE)
- - - 2.98% 1.94% 3.16% 3.78% 6.36% 4.50% 6.46% 7.12%
Cost of Revenue to Revenue
38.99% 37.60% 40.27% 41.10% 43.15% 40.47% 39.52% 37.07% 37.05% 36.56% 35.71%
SG&A Expenses to Revenue
34.67% 33.13% 30.82% 29.40% 29.93% 28.35% 27.40% 25.52% 29.34% 27.42% 27.94%
R&D to Revenue
15.36% 13.54% 13.62% 12.53% 14.02% 12.81% 13.02% 11.77% 12.19% 11.69% 12.02%
Operating Expenses to Revenue
50.03% 46.67% 44.44% 41.93% 43.95% 41.15% 40.43% 37.29% 41.53% 39.11% 39.96%
Earnings before Interest and Taxes (EBIT)
133 188 177 211 154 241 352 341 270 318 335
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
185 240 233 269 214 304 416 406 337 386 409
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
23.85 18.52 13.57 14.45 11.77 13.30 9.68 9.43 8.17 9.91 12.84
Price to Tangible Book Value (P/TBV)
25.52 19.63 14.53 15.37 12.42 13.90 10.06 9.76 8.42 10.41 13.44
Price to Revenue (P/Rev)
14.10 11.46 6.79 7.53 6.43 7.96 5.84 5.55 5.02 5.23 6.38
Price to Earnings (P/E)
83.83 67.61 39.46 52.72 49.86 59.89 36.61 30.95 25.98 26.00 32.86
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
1.19% 1.48% 2.53% 1.90% 2.01% 1.67% 2.73% 3.23% 3.85% 3.85% 3.04%
Enterprise Value to Invested Capital (EV/IC)
29.75 25.35 13.92 15.39 13.16 16.15 13.78 12.64 12.89 13.19 16.31
Enterprise Value to Revenue (EV/Rev)
13.97 11.29 6.78 7.50 6.37 7.85 5.65 5.39 4.77 5.09 6.27
Enterprise Value to EBITDA (EV/EBITDA)
54.47 43.87 28.04 32.63 27.64 33.07 21.20 18.75 15.72 16.37 20.81
Enterprise Value to EBIT (EV/EBIT)
68.25 55.03 36.04 42.65 36.16 43.03 26.60 23.09 19.11 19.75 25.34
Enterprise Value to NOPAT (EV/NOPAT)
99.28 78.84 46.65 62.01 57.04 67.37 43.65 35.87 28.79 28.42 33.30
Enterprise Value to Operating Cash Flow (EV/OCF)
66.22 49.82 32.63 30.56 27.41 34.16 17.62 17.44 12.90 14.46 22.62
Enterprise Value to Free Cash Flow (EV/FCFF)
137.26 92.43 115.26 100.22 109.85 206.41 38.66 37.12 22.46 23.83 37.62
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
1.08 1.00 1.23 1.16 1.08 0.95 0.90 0.45 0.42 0.47 0.49
Long-Term Debt to Equity
1.08 1.00 1.23 0.59 0.55 0.48 0.45 0.45 0.42 0.47 0.49
Financial Leverage
-0.24 -0.25 -0.17 -0.10 -0.16 -0.23 -0.20 -0.18 -0.27 -0.23 -0.28
Leverage Ratio
2.68 3.00 3.05 3.06 2.93 2.82 2.94 2.65 2.56 2.65 2.61
Compound Leverage Factor
2.68 3.00 3.05 3.06 2.93 2.82 2.94 2.65 2.56 2.65 2.61
Debt to Total Capital
52.02% 50.04% 55.21% 53.73% 51.88% 48.72% 47.30% 31.12% 29.58% 32.16% 32.91%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 26.51% 25.59% 24.04% 23.33% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
52.02% 50.04% 55.21% 27.22% 26.29% 24.69% 23.97% 31.12% 29.58% 32.16% 32.91%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
47.98% 49.96% 44.79% 46.27% 48.12% 51.28% 52.70% 68.88% 70.42% 67.84% 67.09%
Debt to EBITDA
2.50 2.41 2.55 2.63 2.56 2.40 2.03 0.93 0.85 0.80 0.81
Net Debt to EBITDA
-0.47 -0.67 -0.06 -0.15 -0.27 -0.47 -0.73 -0.57 -0.80 -0.46 -0.37
Long-Term Debt to EBITDA
2.50 2.41 2.55 1.33 1.30 1.21 1.03 0.93 0.85 0.80 0.81
Debt to NOPAT
4.55 4.33 4.24 5.01 5.27 4.88 4.19 1.77 1.55 1.40 1.29
Net Debt to NOPAT
-0.86 -1.21 -0.09 -0.28 -0.56 -0.97 -1.50 -1.08 -1.47 -0.79 -0.60
Long-Term Debt to NOPAT
4.55 4.33 4.24 2.54 2.67 2.47 2.12 1.77 1.55 1.40 1.29
Altman Z-Score
9.06 7.69 5.20 5.49 4.88 5.66 4.78 6.13 5.74 5.95 7.30
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
2.90 2.82 2.46 1.47 1.50 1.52 1.56 1.88 1.95 1.73 1.74
Quick Ratio
2.43 2.36 2.01 1.22 1.27 1.29 1.33 1.50 1.58 1.36 1.33
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-36 38 -227 -50 -131 -179 271 230 414 421 159
Operating Cash Flow to CapEx
367.66% 422.69% 179.41% 241.89% 211.26% 322.00% 819.75% 288.52% 686.16% 317.83% 615.50%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.63 0.58 0.61 0.63 0.63 0.61 0.65 0.73 0.72 0.72 0.74
Accounts Receivable Turnover
4.71 4.64 4.42 4.07 3.89 3.75 4.28 4.20 4.29 3.81 4.45
Inventory Turnover
2.96 2.96 2.79 2.89 2.99 3.11 3.11 3.18 3.01 2.88 2.72
Fixed Asset Turnover
3.48 3.48 3.30 3.29 3.35 0.00 3.24 3.22 3.30 0.00 3.39
Accounts Payable Turnover
1.17 1.08 1.02 1.09 1.07 1.01 1.05 1.05 0.99 0.90 0.93
Days Sales Outstanding (DSO)
77.55 78.65 82.51 89.58 93.88 97.34 85.34 86.98 84.99 95.73 82.08
Days Inventory Outstanding (DIO)
123.31 123.39 130.69 126.13 122.26 117.42 117.37 114.96 121.21 126.94 134.39
Days Payable Outstanding (DPO)
311.37 339.32 357.24 335.36 340.25 361.58 347.56 346.25 370.42 404.70 390.81
Cash Conversion Cycle (CCC)
-110.52 -137.28 -144.04 -119.65 -124.11 -146.82 -144.85 -144.32 -164.22 -182.04 -174.34
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
1,786 1,751 1,926 1,965 2,009 2,089 1,851 1,988 1,784 1,917 1,961
Invested Capital Turnover
2.22 2.30 2.25 2.15 2.19 2.24 2.39 2.36 2.54 2.48 2.68
Increase / (Decrease) in Invested Capital
148 83 342 186 223 337 -76 24 -225 -172 110
Enterprise Value (EV)
53,129 44,406 26,812 30,239 26,428 33,743 25,513 25,128 22,996 25,284 31,988
Market Capitalization
53,590 45,089 26,865 30,377 26,686 34,227 26,388 25,885 24,170 25,989 32,562
Book Value per Share
$5.76 $6.12 $4.94 $5.38 $5.80 $6.56 $6.95 $7.04 $7.68 $6.79 $6.72
Tangible Book Value per Share
$5.38 $5.77 $4.61 $5.06 $5.50 $6.28 $6.69 $6.80 $7.46 $6.47 $6.42
Total Capital
4,683 4,872 4,419 4,544 4,710 5,018 5,173 3,987 4,199 3,864 3,779
Total Debt
2,436 2,438 2,440 2,441 2,443 2,445 2,447 1,241 1,242 1,243 1,244
Total Long-Term Debt
2,436 2,438 2,440 1,237 1,238 1,239 1,240 1,241 1,242 1,243 1,244
Net Debt
-461 -683 -53 -138 -258 -484 -875 -758 -1,173 -704 -574
Capital Expenditures (CapEx)
57 66 111 125 87 94 81 102 77 85 53
Debt-free, Cash-free Net Working Capital (DFCFNWC)
130 5.50 36 -5.60 21 -1.70 -232 -108 -307 -218 -155
Debt-free Net Working Capital (DFNWC)
3,027 3,126 2,528 2,574 2,722 2,928 3,090 1,891 2,108 1,729 1,663
Net Working Capital (NWC)
3,027 3,126 2,528 1,369 1,517 1,722 1,884 1,891 2,108 1,729 1,663
Net Nonoperating Expense (NNE)
-35 -23 -19 -16 -14 -21 -88 -14 -11 0.63 -6.16
Net Nonoperating Obligations (NNO)
-461 -683 -53 -138 -258 -484 -875 -758 -1,173 -704 -574
Total Depreciation and Amortization (D&A)
53 52 55 58 60 63 64 65 67 68 75
Debt-free, Cash-free Net Working Capital to Revenue
3.41% 0.14% 0.91% -0.14% 0.50% -0.04% -5.13% -2.31% -6.38% -4.39% -3.03%
Debt-free Net Working Capital to Revenue
79.61% 79.45% 63.94% 63.82% 65.62% 68.07% 68.43% 40.56% 43.75% 34.79% 32.59%
Net Working Capital to Revenue
79.61% 79.45% 63.94% 33.95% 36.56% 40.03% 41.71% 40.56% 43.75% 34.79% 32.59%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.38 $0.36 $0.34 $0.38 $0.27 $0.46 $0.73 $0.68 $0.52 $0.65 $0.73
Adjusted Weighted Average Basic Shares Outstanding
390.20M 399.20M 394.20M 393.60M 391.10M 392.10M 391.10M 390.20M 385.10M 382.20M 374.70M
Adjusted Diluted Earnings per Share
$0.36 $0.35 $0.34 $0.37 $0.27 $0.45 $0.70 $0.67 $0.51 $0.64 $0.72
Adjusted Weighted Average Diluted Shares Outstanding
416.70M 416.80M 410.20M 412.70M 407.50M 408.20M 407.40M 405.50M 393.60M 390.10M 383.50M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
397.68M 400.73M 390.60M 390.77M 392.11M 392.16M 390.02M 384.86M 385.87M 377.36M 372.95M
Normalized Net Operating Profit after Tax (NOPAT)
71 121 115 136 91 159 195 253 189 250 269
Normalized NOPAT Margin
7.68% 12.02% 11.60% 12.18% 8.82% 13.70% 16.15% 20.12% 15.86% 19.09% 20.00%
Pre Tax Income Margin
14.39% 18.70% 17.84% 18.98% 14.89% 20.84% 29.13% 27.05% 22.61% 24.27% 24.89%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 74.97% 183.61% 130.16% 0.00% 0.00% 25.97% 59.79% 0.00% 110.39% 132.84%

Financials Breakdown Chart

Key Financial Trends

DexCom’s financial statements show a company that has continued to expand revenue and profitability, although recent cash trends and working-capital movements warrant closer attention. The latest reported period is Q2 2026, and several prior-period figures are marked as restated, so investors should focus on the reported trends rather than comparing individual figures without considering those revisions.

Revenue growth has remained strong. Quarterly revenue increased from $815.2 million in Q4 2022 to $1.31 billion in Q2 2026. On a year-over-year basis, Q2 revenue rose approximately 13% from $1.16 billion in Q2 2025. The sequential increase from $1.19 billion in Q1 2026 was approximately 9.8%, indicating continued commercial momentum.

Profitability has improved meaningfully. Q2 2026 gross profit was $830.0 million, producing a gross margin of approximately 63.4%, compared with 59.5% in Q2 2025. Operating income increased to $318.3 million from $255.3 million in Q1 2026, while the operating margin reached approximately 24.3%. Net income rose to $249.1 million, or $0.64 per diluted share, from $179.8 million, or $0.45 per diluted share, in Q2 2025.

Operating expenses are growing more slowly than revenue over the longer period. From Q2 2023 to Q2 2026, revenue increased about 50%, while total operating expenses rose from $418.3 million to $511.7 million. This operating leverage has helped DexCom expand its operating margin from approximately 14.7% in Q2 2023 to 24.3% in the latest quarter.

Cash generation remains positive but uneven. DexCom generated $269.2 million in operating cash flow during Q2 2026, compared with $303.0 million in Q2 2025 and $525.6 million in Q1 2026. The latest quarter included a $97.9 million use of cash from operating assets and liabilities, reversing the $214.7 million benefit recorded in Q1. Investing cash flow was positive primarily because of $525.8 million in investment sales and maturities, rather than because of free cash flow alone.

The balance sheet remains liquid, but its cash cushion has narrowed. Cash and equivalents plus short-term investments totaled approximately $1.95 billion at the end of Q2 2026, down from $3.63 billion in Q2 2023 and $3.12 billion in Q2 2024. DexCom’s total debt has declined substantially over the same period, while shareholders’ equity has increased. Accounts receivable and inventory also rose sequentially in Q2 2026, which could pressure near-term cash conversion if those balances do not normalize.

  • Sustained revenue expansion: Quarterly revenue increased from $815.2 million in Q4 2022 to $1.31 billion in Q2 2026, with Q2 2026 revenue up approximately 13% year over year.
  • Improving operating leverage: The operating margin expanded to approximately 24.3% in Q2 2026 from about 14.7% in Q2 2023 as revenue growth outpaced operating-expense growth.
  • Higher earnings and EPS: Q2 2026 net income increased to $249.1 million, while diluted EPS reached $0.64, compared with $179.8 million and $0.45, respectively, in Q2 2025.
  • Gross-margin recovery: Gross margin improved to approximately 63.4% in Q2 2026 from 59.5% in Q2 2025, supporting stronger operating profitability.
  • Debt reduction: Total reported debt fell from approximately $3.20 billion in Q2 2023 to $1.24 billion in Q2 2026, reducing balance-sheet leverage and refinancing risk.
  • Positive operating cash flow: DexCom has generated positive operating cash flow in each supplied quarter, including $269.2 million in Q2 2026.
  • Growing shareholders’ equity: Total equity increased to $2.62 billion in Q2 2026 from $2.10 billion in Q2 2023, supported by retained earnings and ongoing profitability.
  • Investment portfolio activity: Investment sales and maturities have frequently produced positive investing cash flow, but this reflects the timing of portfolio transactions and is not the same as recurring operating cash generation.
  • Declining liquid investments: Cash and short-term investments declined to approximately $1.95 billion in Q2 2026 from more than $3.6 billion in Q2 2023, limiting the company’s excess liquidity compared with prior years.
  • Working-capital pressure: Accounts receivable rose to $1.26 billion and inventory increased to $726.4 million in Q2 2026, while changes in operating assets and liabilities consumed $97.9 million of cash during the quarter.

Overall, the statements point to a favorable earnings trend driven by revenue growth, margin expansion and lower debt. However, investors should monitor whether operating cash flow rebounds, whether receivables and inventory convert efficiently into cash, and whether continued financing outflows or capital returns further reduce DexCom’s liquidity.

11/16/26 09:24 PM ETAI Generated. May Contain Errors.

DexCom Financials - Frequently Asked Questions

According to the most recent income statement we have on file, DexCom's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

DexCom's net income appears to be on an upward trend, with a most recent value of $836.30 million in 2025, compared with -$57.60 million in 2015. The previous period was $576.20 million in 2024. Check out DexCom's forecast to explore projected trends and price targets.

DexCom's total operating income in 2025 was $911.80 million, based on the following breakdown:
  • Total Gross Profit: $2.80 billion
  • Total Operating Expenses: $1.89 billion

Over the last 10 years, DexCom's total revenue changed from $402 million in 2015 to $4.66 billion in 2025, a change of 1,059.7%.

In the past 11 quarters, DexCom's cash and equivalents has ranged from $566.30 million in Q4 2023 to $1.84 billion in Q3 2025, and is currently $961.40 million as of their latest financial filing in Q3 2026.

DexCom had total debt of $1.24 billion at the end of 2025, a 49.2% decrease from 2024, and a 53,852.2% increase since 2015.

Over the last 10 years, DexCom's book value per share changed from 2.72 in 2015 to 7.04 in 2025, a change of 158.8%.



Financial statements for NASDAQ:DXCM last updated on 10/29/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners